 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This is a signal that RLAY's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Relay Therapeutics (RLAY, $8.81) RSI Indicator left the oversold zone on September 20, 2023

Relay Therapeutics (RLAY, $9) RSI Indicator left the oversold zone on September 18, 2023

CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...

Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

RLAY's total volume now sits at 4.7M. The +-2.50% price change was insignificant, leaving IBM's price at $9.37...

The volume for Relay Therapeutics stock increased for one day, resulting in a record-breaking daily growth of 337% of the 65-Day Volume Moving Average

Great Point Partners LLC bought a new stake in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY  Free Report) in the 1st quarter, according to its most recent Form 13F filing with the...

Great Point Partners LLC Buys New Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY)

This indicator may be signaling that RLAY's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Relay Therapeutics (RLAY, $10.22) entered Downtrend as Momentum indicator drops below 0 level on Aug 31, 2023

California State Teachers Retirement System trimmed its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY Free Report) by 1.2% in the first quarter, HoldingsChannel reports. The institutional investor owned 100,702 shares of the companys stock after selling 1,272 shares during the period. ...

Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Sold by California State Teachers Retirement System

Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY Get Free Report) have been assigned a consensus recommendation of Moderate Buy from the ten ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation, seven have issued...

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of "Moderate Buy" from Analysts

Relay Therapeutics, Inc. (NASDAQ:RLAY  Free Report)  Research analysts at HC Wainwright reduced their Q3 2023 earnings per share estimates for shares of Relay Therapeutics in a report released on Thursday, August 17th. HC Wainwright analyst R. Burns now anticipates that the company ...

Relay Therapeutics, Inc. Forecasted to Post Q3 2023 Earnings of ($0.87) Per Share (NASDAQ:RLAY)

Relay Therapeutics, Inc. (NASDAQ:RLAY  Get Free Report) shares were down 5.7% during mid-day trading on Tuesday . The stock traded as low as $10.50 and last traded at $10.52. Approximately...

Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 5.7%

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

Watchers	690
52-Wk Low	$8.36
52-Wk High	$24.40

Market Cap	$1.03B
Volume (M)	738,955.00
52-Wk High	$24.40
52-Wk Low	$8.36

RLAY Relay Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals